Navigation Links
Protalix BioTherapeutics, Inc. Receives Approval from the FDA to,Initiate a Phase III Clinical Trial of prGCD

Phase III clinical trial may commence shortly

CARMIEL, Israel, April 18, 2007 /PRNewswire-FirstCall/ --- Protalix BioTherapeutics, Inc. today announced that it has received written notice from the United States Food and Drug Administration (FDA) that it may initiate a Phase III clinical trial in the United States of its lead product candidate, prGCD, a proprietary plant cell expressed recombinant form of human Glucocerebrosidase (GCD), for the treatment of Gaucher Disease, a lysosomal storage disorder in humans.

The FDA has allowed the Company to directly initiate Phase III based upon the results of the Company's pre clinical and Phase I clinical trials of prGCD. The Company presented the completed data from its Phase I clinical trial at the European Working Group of Gaucher Disease (WEGGD) in Cambridge, United Kingdom in July 2006.

The Company hopes to commence the Phase III clinical trial shortly. The trial will take place in centers in the United States, Israel, where approval from the Israeli Ministry of Health has been received, and other locations worldwide. The study will initially consist of male and female adult patients with Gaucher Disease.

David Aviezer, Ph.D., President and Chief Executive Officer of Protalix BioTherapeutics, commented, "The receipt of the FDA's approval to initiate a Phase III clinical trial of prGCD represents an important milestone in the development of this product, and we are excited about the progress we have made thus far. Following the success of our Phase I trial and our promising pre clinical and biochemical data, we believe that we will continue to see positive results from our patients in Phase III."

Dr. Aviezer continued, "We remain deeply committed to the development of a treatment for Gaucher Disease and are excited by the opportunity to commence the Phase III trial and working with the medical experts and patient community."

About
'"/>




Page: 1 2 3

Related medicine technology :

1. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
2. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
3. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:5/4/2015)... Former NASA scientist Tamim Hamid ... he discussed Theradome™, the first portable and wearable OTC ... shows firsthand how, via laser technology, Theradome™ offers individuals ... will not require surgery or medication.  ... of the hair follicle, which is where the stem ...
(Date:5/4/2015)... PAREXEL International Corporation (NASDAQ: PRXL ) announced ... Conference on Monday, May 18, 2015, in New York City.  ... Officer will be making a presentation on PAREXEL and discussing ... webcast of the presentation will be available through the "Investors" ... Upcoming Events portion of the main page, and a replay ...
(Date:5/4/2015)... May 4, 2015 Rogne Bioscience, a privately-held ... announced that preclinical and mechanism of action data will ... of Investigative Dermatology (SID) Annual Meeting being held May ... Atlanta, Georgia . Logo - http://photos.prnewswire.com/prnh/20150501/213318LOGO ... of RON2315, a novel, low MW (<1700 daltons) peptide ...
Breaking Medicine Technology:FOX News Features Theradome as the Take-Home Solution to Tackle Baldness 2PAREXEL International to Present at UBS Healthcare Conference 2Rogne Bioscience to Present Data from Topical Biologic Psoriasis Program at Upcoming SID Annual Meeting 2015 2
(Date:5/4/2015)... 04, 2015 Ticket Down is a reputable ... Cup (ICC) . While the World Cup is the ... every four years, the International Champions Cup is one of ... the all-time attendance record for soccer in the United States ... House at the University of Michigan. This year, the defending ...
(Date:5/4/2015)... Angeles, CA (PRWEB) May 04, 2015 ... Sands, is now offering a more comfortable and attractive ... the restoration of choice for those who have lost ... Dentures can feel insecure or slip at the worst ... patient eats or talks. They can also painfully pinch ...
(Date:5/4/2015)... 2015 New findings released today from ... (ABTA) show that people diagnosed with a brain tumor ... including clinical trials, at the time of diagnosis, and ... decisions about their course of treatment. The release of ... nationwide brain tumor volunteer network, the ABTA CommYOUnityâ„¢, dedicated ...
(Date:5/4/2015)... San Diego, CA (PRWEB) May 04, 2015 ... hosted a ribbon cutting ceremony at their brand new, ... of this year. The new building will not only ... patient population, but will also offer community and educational ... , The new facility is located next door to ...
(Date:5/4/2015)... Helena, MT (PRWEB) May 04, 2015 ... partnered with Care to Care, LLC to manage outpatient ... will help New West Medicare ensure its members are ... avoid unnecessary radiation. , Working closely with New West ... in promoting the safe use of advanced imaging and ...
Breaking Medicine News(10 mins):Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 2Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 3Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 4Health News:Los Angeles Dental Implants Doctor, Kevin Sands DDS, Now Offers a More Comfortable and Aesthetically-Pleasing Solution to Denture-Wearers 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 3Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 3Health News:New West Medicare Partners with Care to Care, LLC to Manage Advanced Imaging Services 2
... researchers say , , WEDNESDAY, Jan. 30 (HealthDay News) -- ... a Canadian study that found that DBS of the ... , DBS -- which involves electrical stimulation of ... disease and other movement disorders, and is being studied ...
... known to doctors as a hormone that boosts red-blood-cell production. ... PhD, an ophthalmologist at Children,s Hospital Boston, shows it also ... The findings not only add a new function to the ... prescribing it to patients with diseases affected by abnormal blood-vessel ...
... Caraco Pharmaceutical,Laboratories, Ltd. (Amex: CPD ) ... Tablets, 40 mg (Pantoprazole Sodium,DR), which is AB-rated ... Sun,Pharmaceutical Industries, Ltd. (Sun Pharma). Sun Pharma recently ... (FDA) for its Abbreviated,New Drug Application (ANDA) for ...
... CALL DATE: Wednesday, Feb. 27, 2008 ... 8:30 a.m. Eastern Time ... Chairman and CEO Kendle (Nasdaq: KNDL ) will conduct a telephone conference ... for the Fourth Quarter and Year Ended Dec. 31, 2007. A,question and answer session ...
... Stryker Corporation,(NYSE: SYK ) announced today that it ... at 8:00 a.m. Eastern Time, in New York, New ... Officer, will host,the meeting with presentations by leaders of ... the meeting will be available on Stryker,s,website at ...
... Crowell & Moring LLP is,pleased to announce the ... office as a member of the firm,s Antitrust and ... she helped found and co-chair,the firm,s Healthcare Industry Group. ... Trade Commission (FTC), where she investigated and,prosecuted mergers, joint ...
Cached Medicine News:Health News:Deep Brain Stimulation May Improve Recall 2Health News:Anemia treatment may be a double-edged sword 2Health News:Anemia treatment may be a double-edged sword 3Health News:Caraco Pharmaceutical Laboratories Ltd. to Market Generic Protonix(R) 2Health News:Caraco Pharmaceutical Laboratories Ltd. to Market Generic Protonix(R) 3Health News:Kendle Invites You to Attend Its Fourth Quarter and Year End 2007 Earnings Conference Call and Webcast 2Health News:Stryker to Host Analyst Meeting 2Health News:Former FTC Attorney Christine White Joins Crowell & Moring's Health Care and Antitrust Groups 2Health News:Former FTC Attorney Christine White Joins Crowell & Moring's Health Care and Antitrust Groups 3
Liquichek Pediatric Control is a product designed to monitor important analytes for neonatal testing. This control monitors four bilirubin parameters at two clinically significant levels....
... Chemistry Control (Human) provides a comprehensive ... enzymes and CO2. It requires no ... most major instruments and methodologies. Available ... fill sizes (10 mL fill size ...
Liquid Assayed and Unassayed Multiqual Controls are comprehensive, liquid, human serum based chemistry controls, available in three levels....
Lyphochek® Drug Free Serum can serve as a drug-free baseline for HPLC analysis or as a negative control....
Medicine Products: